EnteroMedics (RSLS) Given Daily Coverage Optimism Rating of 0.17
Headlines about EnteroMedics (NASDAQ:RSLS) have been trending somewhat positive this week, according to Accern Sentiment. The research group scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. EnteroMedics earned a coverage optimism score of 0.17 on Accern’s scale. Accern also assigned press coverage about the medical device company an impact score of 47.14 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the news stories that may have impacted Accern Sentiment Analysis’s scoring:
- Here Are Two Things We’re Looking For From Reshape Lifesciences Inc (NASDAQ:RSLS) – Insider Financial (insiderfinancial.com)
- ReShape Lifesciences To Host Third Quarter Conference Call On November 14, 2017 – Markets Insider (markets.businessinsider.com)
- Rising P/E: An Overlooked Way to Reach 5 Winning Stocks – Nasdaq (nasdaq.com)
EnteroMedics (NASDAQ:RSLS) last released its quarterly earnings data on Tuesday, August 8th. The medical device company reported ($0.91) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.09. The business had revenue of $0.09 million for the quarter, compared to analysts’ expectations of $0.20 million. EnteroMedics had a negative return on equity of 167.73% and a negative net margin of 4,399.48%.
Several brokerages have recently weighed in on RSLS. ValuEngine lowered shares of EnteroMedics from a “sell” rating to a “strong sell” rating in a report on Monday, October 2nd. Zacks Investment Research upgraded shares of EnteroMedics from a “hold” rating to a “strong-buy” rating and set a $2.25 price objective on the stock in a report on Wednesday, August 23rd.
EnteroMedics Company Profile
ReShape Lifesciences Inc, formerly EnteroMedics Inc, is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve.
Receive News & Ratings for EnteroMedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EnteroMedics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.